Jeff S. Aronin: A Leader in Global Biopharmaceuticals

Jeff S. Aronin states, “Problems people have deemed unsolvable are the problems we are solving.” That philosophy is the guiding principle of Paragon Biosciences, a biopharmaceutical investment firm and global leader in healthcare development. Diseases, and more importantly, diseases that have no known treatment, impede a person’s quality of life. More than 6,000 known diseases do not have a drug treatment plan to mitigate the disease by either lessening the severity of the symptoms or decreasing the pain associated with the disease. Jeff S. Aronin and Paragon Biosciences are committed to improving the lives of patients by investing in innovative biotechnology companies ( Starting with the needs of patients and through innovation and cutting-edge technology, Jeff S. Aronin and his team invest in companies that develop drugs to combat diseases that do not currently have a treatment plan available.

There are four companies under the portfolio of Paragon Biosciences. Castle Creek Pharmaceuticals focuses on treatments for persons living with dermatologic conditions that are rare, serious or debilitating. Seeking innovative treatment for patients living with diseases of the central nervous system is Harmony Biosciences. Decade is an R&D company focusing on identifying treatment for Alzheimer’s disease and Precision BP works on the development of treatments for those living with rare genetic oncology diseases.

The success of Paragon Biosciences in meeting the needs of patients is dependent upon a team passionate about improving the quality of life of those living with diseases for which there is no available treatment. Jeffery S. Aronin, the chairman and CEO of Paragon Biosciences head this team of innovative leaders. Mr. Aronin has been involved as president and chief executive officer in biopharmaceuticals since 2000 and he has served as the chairman and CEO of Paragon Biosciences since 2010. In addition to being a transformational leader, Jeff also has considerable expertise in strategic and business development including mergers and acquisitions, as well as finance and brand marketing.


Leave a Reply

Your email address will not be published. Required fields are marked *